,33 Luxturna, the first FDA-approved gene therapy for an inherited disease, utilizes AAV2 vectors to deliver a normal copy of the RPE65 gene to retinal cells, addressing mutations that cause Leber congenital amaurosis (LCA).34 This evidence concerns the gene RPE65 and Leber congenital amaurosis.